U of L researcher publishes study indicating drug for HIV prevention - Business First of Louisville:

hihozeima.blogspot.com
The Owensboro Cancer Research Program is a partnership betweenn the Owensboro Medical Health Systek and Uof L’ws James Graham Brown Cancer HIV research is a focus of the program because HIV patientas have a higher risk of gettingh cancer. Palmer was the senior author of the which was published today in the Proceedings ofthe . It indicates that a protein found in a plangcalled “nicotiana benthamiana” could be a low-cosf measure to prevent the which can lead to AIDS. The publishexd study was a collaborative effort between Palmer andothee scientists, including Dr. Barry O’Keefe of the .
Two Kentucky-based biotech companies, LLC and , also participated in the along with researchers at andthe , according to a news Palmer, also an associate professor of pharmacology and toxicology and senior scientisf at the Brown Cancer Center, said durinf a news conference today that researchers have developed a procesws that allows 500,000 potentiaol human doses to be extracted from plants grown in a 5,000-square-foo t greenhouse. The protein could be manufactured into a gel or a Palmer said, and could be comparable in cost to male Such a product would be especially useful in developing countries for women who are not able to condom use with sexual partners, Palmer said.
“Ther e is a big need for an effective, female-controlleed intervention,” he said, adding that the potentiaol demand equatesto “billions of doses.” The plante from which the protei is extracted could be grown in Palmer said, and could represenr opportunity for the agriculture industry. “I think that it coul d be a new way of and I hopeit is,” he said. The next Palmer said, is to formulate the proteinb so that it can be usedin early-stag clinical trials in humans. Researcher s hope to begin a phase one trial sometimeenext year, Palmer said, and the treatment could reach the markett as soon as 2015.
Palmeer estimated that “tens of millions” of dollars woulcd be needed to carry the projec through phase threeclinical testing. Project leaders believed that internationalhealth organizations, such as the Bill Melinda Gates Foundation, will have an interest in helpingt to fund the research, said Dr. Donald Miller, director of the Brownj Cancer Center. Miller called the newly published stud ya “very important piece of “We think this is a validation of our beliecf that this is goingy to be a very viable, cost-effective way to produces new drugs,” Miller said.
|